Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolimidone - Melior Pharmaceuticals

Drug Profile

Tolimidone - Melior Pharmaceuticals

Alternative Names: CP-26154; MLR-1023

Latest Information Update: 17 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Bukwang Pharmaceutical; Melior Pharmaceuticals, Inc.
  • Class Antihyperglycaemics; Phenyl ethers; Small molecules
  • Mechanism of Action Lyn protein-tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 15 May 2019 Melior files new patents for tolimidone in Non-alcoholic steatohepatitis
  • 15 May 2019 Melior completes a phase II trial in Type-2 diabetes mellitus (Adjunctive treatment) in USA and South Korea (PO) (NCT03279263)
  • 16 Oct 2018 Melior Pharmaceuticals plans a phase II trial for Non-alcoholic steatohepatitis in early 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top